FDA inspections of large volume and small volume parenteral manufacturers.
作者信息
Shepherd R E
出版信息
Bull Parenter Drug Assoc. 1976 Sep-Oct;30(5):209-13.
PMID:974306
Abstract
摘要
相似文献
1
FDA inspections of large volume and small volume parenteral manufacturers.
Bull Parenter Drug Assoc. 1976 Sep-Oct;30(5):209-13.
2
Response to the applicability of proposed large volume parenteral regulations to small volume parenteral drug products.对拟议的大容量注射剂法规适用于小容量注射剂药品的回应。
Bull Parenter Drug Assoc. 1976 Nov-Dec;30(6):265-79.
3
The brand name versus generic controversy: Is there a segment of the pharmaceutical industry that produces drugs of higher quality?品牌药与仿制药之争：制药行业中是否存在生产质量更高药品的细分领域？
Contemp Pharm Pract. 1982 Spring;5(2):130-5.
4
Products in the U.S. pipeline. Pharmaceutical Manufacturers Association.
Biotechnology (N Y). 1991 Oct;9(10):947-9.
5
FDA-USP drug product problem reporting program--an update.
Hosp Formul. 1979 Mar;14(3):359-60, 365.
6
Biopharmaceutic equivalency and the role of the Food & Drug Administration.
Am J Hosp Pharm. 1968 Mar;25(3):121-7.
7
Regulatory aspects of parenteral drugs.注射用药物的监管方面。
Bull Parenter Drug Assoc. 1972 Mar-Apr;26(2):53-7.
8
Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers.严重药品不良反应评估：主动式药物警戒计划（RADAR）与美国食品药品监督管理局及制药企业开展的安全性活动对比
Arch Intern Med. 2007 May 28;167(10):1041-9. doi: 10.1001/archinte.167.10.1041.
9
Recommendations for the labeling of large volume parenterals. National Coordinating Committee on Large Volume Parenterals.
Am J Hosp Pharm. 1978 Jan;35(1):49-51.
10
Drug safety: the viewpoint of the pharmaceutical manufacturing industry.药物安全性：制药行业的观点
Can Med Assoc J. 1968 Feb 10;98(6):314-7.
Zotero 插件